SLC31A2

Chr 9

solute carrier family 31 member 2

Also known as: COPT2, CTR2, hCTR2

The protein functions as a regulator of SLC31A1 by facilitating cleavage of the SLC31A1 ecto-domain and stabilizing its truncated form, thereby modulating endosomal copper export and cellular copper accumulation. Despite being predicted to cause disease through a dominant-negative mechanism, no specific diseases have been definitively associated with SLC31A2 mutations in humans. The gene shows high tolerance to loss-of-function variants, suggesting haploinsufficiency is unlikely to be pathogenic.

Summary from RefSeq, UniProt, Mechanism
Research Assistant →
0
Active trials
3
Pubs (1 yr)
0
P/LP submissions
P/LP missense
1.80
LOEUF
Multiple*
Mechanism· predicted
Clinical SummarySLC31A2
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.80LOEUF
pLI 0.000
Z-score -0.06
OE 1.03 (0.561.80)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
0.57Z-score
OE missense 0.82 (0.671.01)
64 obs / 78.2 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE1.03 (0.561.80)
00.351.4
Missense OE0.82 (0.671.01)
00.61.4
Synonymous OE0.77
01.21.6
LoF obs/exp: 6 / 5.8Missense obs/exp: 64 / 78.2Syn Z: 1.04
DN
0.76top 25%
GOF
0.72top 25%
LOF
0.2387th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

SLC31A2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC

No open access results found